iRadimed Corporation (NASDAQ:IRMD) Receives $120.00 Consensus PT from Analysts

Shares of iRadimed Corporation (NASDAQ:IRMD) have been given a consensus rating of “Moderate Buy” by the five ratings firms that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $120.00.

Several research analysts have recently commented on the stock. Weiss Ratings lowered shares of iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, August 3rd. Wall Street Zen lowered shares of iRadimed from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th.

Insider Activity

In other iRadimed news, CEO Roger E. Susi sold 2,500 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $90.60, for a total value of $226,500.00. Following the transaction, the chief executive officer owned 2,162,500 shares in the company, valued at $195,922,500. The trade was a 0.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 10,000 shares of company stock worth $883,750 in the last ninety days. 34.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On iRadimed

Several hedge funds have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of iRadimed in the second quarter worth about $92,485,000. Vanguard Group Inc. raised its stake in shares of iRadimed by 1.0% in the third quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider’s stock valued at $40,313,000 after acquiring an additional 5,475 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in iRadimed by 410.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock worth $24,893,000 after acquiring an additional 205,783 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of iRadimed by 4.2% during the first quarter. Dimensional Fund Advisors LP now owns 226,146 shares of the medical equipment provider’s stock valued at $21,768,000 after acquiring an additional 9,017 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in iRadimed by 37.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock worth $19,964,000 after acquiring an additional 55,426 shares during the period. 92.34% of the stock is owned by institutional investors and hedge funds.

iRadimed Stock Down 0.2%

Shares of NASDAQ:IRMD opened at $86.95 on Monday. The company has a market cap of $1.11 billion, a P/E ratio of 48.58 and a beta of 0.90. iRadimed has a 52 week low of $67.84 and a 52 week high of $107.90. The business has a fifty day simple moving average of $94.17 and a 200-day simple moving average of $94.89.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. The company had revenue of $20.47 million for the quarter, compared to the consensus estimate of $20.35 million. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Sell-side analysts expect that iRadimed will post 1.98 earnings per share for the current fiscal year.

iRadimed Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 28th. Stockholders of record on Friday, August 14th will be given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, August 14th. iRadimed’s dividend payout ratio is 44.69%.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.